Primary care perspectives on obesity pharmacotherapy, initiation thresholds, long-term sustainability, patient expectations, access, and clinical uncertainty.
Audience: Family practitioners and general physicians
Countries: 6
Survey records: 510
– Hero finding
Quick Read — Key Findings
Explore the clinical pattern, the likely reasons behind it, and what it may mean in practice.
// The backstory
Newer obesity medicines have changed what primary care can offer, but starting treatment is not a simple response to a BMI threshold or a patient request.
The decision spans metabolic risk, previous lifestyle treatment, patient expectations, affordability, monitoring, likely duration, response criteria, and what may happen if therapy stops. Earlier prescribing therefore creates a longer clinical responsibility.
The World Health Organization recognises selected GLP-1 medicines as long-term options within comprehensive chronic obesity care. The practical challenge is to translate that direction into patient selection and follow-up that can be sustained in everyday primary care.
Source: World Health Organization guideline and Q&A on GLP-1 therapies for obesity, plus NICE practical prescribing guidance. WHO global guideline announcement; WHO obesity and GLP-1 Q&A; NICE practical prescribing guide
The survey included family practitioners and general physicians from the United States, United Kingdom, Canada, Italy, France, and Germany.
Finding 1
A combined 76.2% report either a fundamental shift toward earlier use or a noticeable but selective increase in prescribing. The largest single group, 40.2%, still describes the change as selective.
What the pattern suggests: The pattern suggests that newer medicines have changed practice without removing clinical thresholds. Primary care is adopting pharmacotherapy, but most clinicians are still deciding which patients should move earlier and which should continue with a staged approach.
Why it matters: This matters because the initiation threshold needs to be explainable. A clear rationale can reduce both passive delay and the impression that treatment is being offered automatically because a medicine is newly available.
Finding 2
For patients with BMI of 30 or more and no major comorbidity, 48.6% wait for a defined period of structured lifestyle intervention. Smaller groups start earlier, wait for worsening, rarely initiate, or vary by context.
What the pattern suggests: The pattern suggests that lifestyle treatment remains both therapeutic and informative. It can show what the patient can sustain, how weight is changing, and whether risk is emerging, but it can also become an indefinite waiting period if the checkpoint is not time-limited.
Why it matters: This matters because primary care needs a clear review point. Lifestyle support should have goals, duration, and criteria for escalation so that a planned trial does not become unstructured delay.
Finding 3
Early signs of metabolic risk lead initiation decisions at 43.1%, ahead of repeated lifestyle failure at 28.3%, quality-of-life impact at 14.5%, rapid gain at 8.8%, and patient request at 5.3%.
What the pattern suggests: The pattern suggests that clinicians are more comfortable moving earlier when obesity is linked to visible cardiometabolic risk. The treatment decision becomes a prevention decision rather than a response to body size alone.
Why it matters: This matters because patients need to understand the risk being addressed. Explaining prediabetes, dyslipidaemia, function, and future disease risk can make the rationale for treatment clearer and less weight-centred.
Finding 4
In borderline cases, 58.4% are more influenced by long-term safety, dependency, or uncertain durability than by the risk of delaying treatment and worsening cardiometabolic outcomes.
What the pattern suggests: The pattern suggests that the decision is shaped by uncertainty on both sides. Clinicians are balancing the known consequences of untreated obesity against unanswered questions about years of therapy, discontinuation, and weight regain.
Why it matters: This matters because shared decisions should compare both risks explicitly. Discussing only treatment uncertainty can make delay look neutral, while discussing only disease risk can minimise legitimate concerns about long-term therapy.
Finding 5
Cost and access are a major limiting factor for 43.8% and a moderate influence for another 30.7%. Together, 74.5% see affordability or availability materially shaping prescribing.
What the pattern suggests: The pattern suggests that the clinically preferred option may be unavailable, unstable, or interrupted. Access can change not only whether treatment starts, but also which medicine is selected and whether the patient can remain on it.
Why it matters: This matters because an access check belongs early in the conversation. Setting expectations before confirming coverage, supply, and follow-up can create frustration and reduce trust when the plan cannot be delivered.
Finding 6
Most clinicians, 58.8%, adapt guidelines to the individual patient, while 18.0% follow them closely in most cases. The rest use them as a general reference, deviate frequently, or rarely rely on them.
What the pattern suggests: The pattern suggests that obesity care is too heterogeneous for uniform application. Comorbidity, function, previous treatment, goals, contraindications, access, and tolerance all influence the final plan.
Why it matters: This matters because individualisation should remain transparent. Documenting why guidance was adapted can preserve consistency, support shared decisions, and distinguish thoughtful variation from unexplained practice differences.
Practice implications
Assess risk beyond BMI
Metabolic risk, function, trajectory, and the burden of waiting should be considered alongside body size.
Set a long-term plan before initiation
The conversation should cover monitoring, expected duration, cost, response criteria, side effects, and what happens if treatment stops.
Keep shared decisions structured
Patient preference matters, but it should be connected to clinical indication, realistic benefit, and the ability to sustain care.
Primary care is clearly moving toward greater use of obesity pharmacotherapy, but the findings do not describe a simple shift from lifestyle care to medicine. They describe a more complex, combined model.
Metabolic risk pulls clinicians toward earlier action, while long-term uncertainty, cost, and the need for sustained follow-up slow the decision. The resulting tension explains why belief in earlier care does not always become earlier prescribing.
The next step is to make the full pathway visible before treatment begins: why the patient is being treated, what benefit is expected, how response will be assessed, how access will be maintained, and what the plan is if therapy is stopped or becomes ineffective.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
You have read the summary
Explore the complete findings in the full report, or join MDForLives to contribute your perspectives to future healthcare research.
//People Also Ask
Direct, current answers to common questions around this topic.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
